Branch Retinal Vein Occlusion (BRVO)

Sponsor - F. Hoffmann-La Roche Ltd. (Closed to Recruitment)

Study: BALATON GR41984
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION
https://clinicaltrials.gov/ct2/show/NCT04740905?term=BALATON&draw=2&rank=1

Sponsor - Kodiak Sciences, Inc. (Closed to Recruitment)

Study: BEACON KS301P103
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO)
https://clinicaltrials.gov/ct2/show/NCT04592419?term=BEACON&cond=REtina&draw=2&rank=1

Sponsor - Patrick Higgins, MD (Recruitment/Open to Enrollment)

Study: IST
Retrospective chart review of the prevalence of positive findings in the hypercoagulability workup on patients with ischemic and nonischemic retinal vein occlusions

Previous Branch Retinal Vein Occlusion (BRVO) Studies:

2019 - 2021
Sponsor - Novartis
Study: Raptor
An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT03802630?term=raptor&rank=2

Sub-Investigator, 2008 - 2010
Sponsor: Genentech
Study: HORIZON
An Open-Label, Multicenter Extension Study To Evaluate The Safety And Tolerability Of Ranibizumab In Subjects With Choroidal Neovascularization (CNV) Secondary To Age-Related Macular Degeneration (AMD) Or Macular Edema Secondary To Retinal Vein Occlusion (RVO) Who Have Completed A Genentech-Sponsored Ranibizumab Study

Sub-Investigator, 2007 - 2010
Sponsor: Genentech
Study: BRAVO
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT00486018?term=BRAVO&cond=Vein+Occlusion%2C+Retinal&rank=1

Sub-Investigator, 2006 - 2009
A Six-Month, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700µg and 350µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein

Sub-Investigator, 2006 - 2009 
NIH SCORE: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion Randomized

Sub-Investigator, 2005
Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection (s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion